Jacobs Levy Equity Management Inc. Takes $703,000 Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Jacobs Levy Equity Management Inc. bought a new stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 232,058 shares of the company’s stock, valued at approximately $703,000. Jacobs Levy Equity Management Inc. owned about 0.33% of Zentalis Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of ZNTL. Graham Capital Management L.P. boosted its holdings in shares of Zentalis Pharmaceuticals by 37.4% in the fourth quarter. Graham Capital Management L.P. now owns 57,946 shares of the company’s stock valued at $176,000 after purchasing an additional 15,760 shares during the period. Deutsche Bank AG boosted its holdings in shares of Zentalis Pharmaceuticals by 34.1% in the fourth quarter. Deutsche Bank AG now owns 42,804 shares of the company’s stock valued at $130,000 after purchasing an additional 10,873 shares during the period. D. E. Shaw & Co. Inc. boosted its holdings in shares of Zentalis Pharmaceuticals by 9.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,239,459 shares of the company’s stock valued at $3,756,000 after purchasing an additional 110,882 shares during the period. Corton Capital Inc. purchased a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $32,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at approximately $546,000.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $1.26 on Friday. The business’s fifty day simple moving average is $1.44 and its 200-day simple moving average is $2.33. The company has a market cap of $90.66 million, a PE ratio of -0.51 and a beta of 1.81. Zentalis Pharmaceuticals, Inc. has a 12-month low of $1.01 and a 12-month high of $13.00.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.67). On average, equities analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Transactions at Zentalis Pharmaceuticals

In other news, Director Scott Dunseth Myers bought 21,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 30th. The shares were purchased at an average cost of $1.40 per share, with a total value of $29,400.00. Following the transaction, the director now directly owns 281,192 shares in the company, valued at approximately $393,668.80. The trade was a 8.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Wedbush reiterated a “neutral” rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday. Wells Fargo & Company lowered their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. UBS Group lowered their target price on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.